Investigation Announcement: Johnson Fistel, PLLP is investigating potential legal claims for Doximity, Inc. shareholders regarding alleged misconduct by company officers and directors.
Legal Rights for Shareholders: Long-term shareholders of Doximity who held shares before June 24, 2021, are encouraged to contact Johnson Fistel to learn about their legal rights.
Court Ruling on Fraud Allegations: A court has denied a motion to dismiss a securities fraud class action against Doximity, finding sufficient evidence that the company misrepresented user engagement and growth prospects.
Johnson Fistel's Credentials: The law firm is recognized for its effectiveness in advocating for investors, having recovered approximately $90.7 million for clients in securities cases, and has been ranked among the top plaintiff law firms.
DOCS
$43.8+Infinity%1D
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 68.46 USD with a low forecast of 55.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 68.46 USD with a low forecast of 55.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
6 Hold
2 Sell
Moderate Buy
Current: 44.650
Low
55.00
Averages
68.46
High
82.00
Current: 44.650
Low
55.00
Averages
68.46
High
82.00
Morgan Stanley
Equal Weight -> Overweight
upgrade
$62 -> $65
2025-12-15
New
Reason
Morgan Stanley
Price Target
$62 -> $65
2025-12-15
New
upgrade
Equal Weight -> Overweight
Reason
Morgan Stanley upgraded Doximity to Overweight from Equal Weight with a price target of $65, up from $62. The firm says the stock's underperformance "is at odds" with its checks on the business and strengthening platform engagement. Doximity's guidance and Street estimates look conservative, the analyst tells investors in a research note. Morgan Stanley sees an attractive entry point at current share levels.
Barclays
Glen Santangelo
Overweight
initiated
$63
2025-12-08
Reason
Barclays
Glen Santangelo
Price Target
$63
2025-12-08
initiated
Overweight
Reason
Barclays analyst Glen Santangelo initiated coverage of Doximity with an Overweight rating and $63 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Raymond James
Outperform -> Strong Buy
upgrade
$75 -> $65
2025-11-21
Reason
Raymond James
Price Target
$75 -> $65
2025-11-21
upgrade
Outperform -> Strong Buy
Reason
Raymond James upgraded Doximity to Strong Buy from Outperform with a price target of $65, down from $75. The stock's risk/reward is "too compelling to ignore" following the post-earnings selloff, the analyst tells investors in a research note. The firm thinks Doximity's long-term growth visibility is improving. Raymond James says the recent pullback has the shares at a discount to the vertical software group that is "too great to ignore."
BMO Capital
Market Perform
initiated
$55
2025-11-12
Reason
BMO Capital
Price Target
$55
2025-11-12
initiated
Market Perform
Reason
BMO Capital initiated coverage of Doximity with a Market Perform rating and $55 price target. Doximity's strong clinician engagement through its social and workflow platform enhances its appeal as a marketing tool for pharmaceutical companies, the analyst tells investors in a research note. While growth opportunities remain through user expansion and monetization, the current valuation suggests much of this potential is already reflected in the share price, BMO says.
About DOCS
Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
